YingBaiRui Announces First Patient Dosed in Phase I Clinical Trial of IBR733, a First-in-Class CD33/CLL1 Bispecific Antibody-Conjugated NK Cell Therapy for Acute Myeloid Leukemia

On April 17, Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. announced that the first patient dosing was successfully completed in the Phase I clinical trial of IBR733 Cell Injection for treating Acute Myeloid Leukemia (AML) at the First Affiliated Hospital of Soochow University. The infusion process went smoothly, and the patient's vital signs remained stable.

IBR733 Cell Injection is the first IND-approved clinical study worldwide for the indication of acute myeloid leukemia.CD33 and CLL1 Dual-Target Antibody-Conjugated NK Cell ProductIt uses imbioray's unique specific antibody CD33/CLL1, which targets tumor antigens, to chemically conjugate with NK cells through a linker. This is an off-the-shelf, universal NK cell product that does not involve viral vectors or genetic modification, offering high safety and potent tumor cell killing ability. The IBR733 cell injection has already been involved in several investigator-initiated clinical trials (IIT), achieving excellent results in both safety and efficacy.

The Phase I clinical trial of IBR733 cell injection is being conducted at renowned clinical research centers in China, including the First Affiliated Hospital of Soochow University, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, the First Affiliated Hospital of Zhejiang University School of Medicine, West China Hospital of Sichuan University, and Zhongda Hospital affiliated with Southeast University. Imbioray will closely collaborate with these research centers to actively advance the clinical development of IBR733, which is expected to bring new treatment options and survival hope to more patients with acute myeloid leukemia.

Hot Topic

Progress in the Clinical Development of NK Cell Therapy

Opportunities and Challenges in the Original Development of Cell Therapy Drugs

Development Strategies for iPSC-Derived NK Cell Therapy in Tumors

Exploration of Payment Methods for CAR-T Cell Therapy

Market Opportunities and Challenges for TIL Therapy

Research Progress of CAR-NK Cell Therapy in the Treatment of Hematological Tumors

Development Strategies for CAR-T Cell Therapy in Glioblastoma

Development and Challenges of CAR-T Cell Therapy Derived from Cord Blood

Clinical Exploration of CLDN18.2-Targeted CAR-T in Solid Tumors

Application of mRNA Technology in CAR Cell Therapy

Advances in TCR-T Cell Therapy for Solid Tumors

Development Strategies for CAR-M Cell Therapy

Roundtable: Feasibility Discussion on the Global Commercialization of Cell Drugs Entering a Boom Period

Roundtable: Technological Innovation Opportunities in Tumor Immunocyte Therapy

Scan the code

Limited Time Offer

Free Tickets

Hotline for Cooperation

18701871600 (Manager Wang)

15572286596 (Manager Yuan)

15221150919 (Manager He)

Imbioray is a clinical-stage and venture capital-backed innovative biopharmaceutical company, primarily focusing on the development of immunotherapy drugs for cutting-edge global oncology immunotherapy, as well as for immune-related diseases, chronic conditions, and CNS disorders.Dr. Miao Zhenwei, the founder of Imbioray, returned to China in 2016 to start a business and established the direction of developing off-the-shelf universal cell drugs based on NK.ImbiorayWith four internationally pioneering core technology platforms to accelerate the company's innovation at the source, and internationally leading large-scale closed-system in vitro cultivation.Advanced Processes of NK Cells.Based on its proprietary antibody-conjugated NK cell platform technology, Imbioray has developed IBR854 and IBR7.33, imbioray's IBR822 and other general off-the-shelf cell therapy products.Currently, IBR854 Cell Injection, the world's first innovative treatment for advanced solid tumors, and IBR733 Cell Injection, the world’s first treatment targeting acute myeloid leukemia, have both entered Phase I clinical trials.IBR822 is Imbioray's third antibody-NK cell conjugate drug, and its IND is currently under CDE review.。

Imbioray is committed to becoming a pioneer and leader in the global NK cell immunotherapy field, with a core focus on patient needs and clinical value, adhering to the concept of "The Light of Immunotherapy, Igniting New Hope for Life."

Live Broadcast Preview

On April 25, Cutting-edge Applications of Cell Analysis Technology Accelerate Innovations in Drug Development and Immunotherapy Research

Statement and Copyright Notice

Disclaimer: This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint, and does not represent the position of EMedClub, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.

Copyright Statement:This article is from the content team of Yi Mai Ke. Individuals are welcome to share it on their social media platforms, but unauthorized reprints by media or organizations in any form to other platforms are prohibited. For reprint authorization, please leave a message below the article.

ImbiorayShare”、“Like" and "In View"，Give me a little recharge~"